Marksans Pharma Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/3htskujqmjyyko7aamd9inzr.pdf

Key Takeaways


US Business: Tariff Clarity Unlocks the Playbook

Mark Saldanha: "I know last six months has been with a pinch of uncertainty. But now with clarity emerging, I think we will be back on track to hit our objectives. We are still targeting 30 crore in a three years."

UK & Europe: Building the Next Leg

Mark Saldanha: "These approvals are not so much topline drivers, but they are more bottom-line drivers."

Margins: Operating Leverage vs. Build-Out Costs


Capacity & Infrastructure: Building for ₹5,000 Crore

Mark Saldanha: "by just shifting capacity into these blocks, we can literally double if not triple our capacity from where we are."

Guidance & Commitments

CommitmentSpecificsTimeline
US order book target₹30 crore order bookIn three years
Revenue target~₹3,000 croreBy next year
Revenue target₹5,000 croreBy FY30 ("fair to say")
UK revenueDouble UK revenuesOver the next 5–7 years
UK sequential improvementQ3 better than Q2; 2026 better than 2025Q3 FY26 / CY2026
UK higher-value launchesMeaningful impact from new product launchesSecond half of calendar 2026 / Q3 FY26
Germany operationsFull flow; results visibleQ1 FY26; second half of 2026
Europe operationsStart in four countries, organically or inorganically2026
Canada launchMarket entryBy 2026
European M&ASmaller M&As across Europe concludedIn '26
Capacity expansionTablets to 120–130 crore; soft gels ~3x; ~₹100 crore CAPEXEnd of 2026 / CAPEX deployed in 2026
New plant US FDA approvalsApprovals from Unit 2 (Teva plant)Expected in '26
Working capital normalizationReturn to 120–130 daysNext two to three quarters
Full-year FY26 EBITDA margin19–20% band; "may be slightly better"FY26
New infrastructure investment triggerInvest when trending toward ₹4,000 crores revenueNo date; condition-based

Key Metrics

MetricQ2 FY26
Operating revenue₹720.4 cr, +12.2% YoY vs ₹642 cr
US & North America revenue₹387 cr, +27% YoY
UK & EU formulation revenue₹245 cr
Australia & New Zealand revenue₹61.3 cr
Rest of world revenue₹26.5 cr
Gross margin57.2%, vs 59.7% last year; product mix and UK pricing pressure
EBITDA₹144.5 cr; EBITDA margin 20.1%, -108 bps YoY, +391 bps QoQ
Profit after tax₹99.1 cr, +1.4% YoY
EPS₹2.2
US order book$225–$230 million
Working capital cycle150 days, improved from Q1 as tariff disruptions eased; expected to return to 120–130 days in 2–3 quarters
Cash balance₹666.5 cr as of 30 Sep 2025; company remains debt-free
H1 R&D spend₹26.2 cr, 2% of consolidated revenue
H1 CAPEX₹73.2 cr
Teva plant (Unit 2) utilization~30% or less
Old Goa plant tablet capacity70–80 crore tablets per month; target 120–130 crore tablets by end of 2026 with ~₹100 cr CAPEX
FY26 EBITDA margin guidance19%–20%, may be slightly better